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1. INTRODUCTION {#cam42169-sec-0005}
===============

Liver cancer ranged as the seventh most common cancer and the fourth leading cause of global cancer deaths (<http://gco.iarc.fr/today/home>). It was estimated that the number of the new liver cancer cases per year was 554,000 for men and 228,000 for women, respectively, over 50% of which occurred in China.[1](#cam42169-bib-0001){ref-type="ref"} Hepatocellular carcinoma (HCC), as the most important pathological of liver cancer, has a poor prognosis (with a poor 5‐year survival rate of about 7% after treatment).[2](#cam42169-bib-0002){ref-type="ref"}, [3](#cam42169-bib-0003){ref-type="ref"} Multiple risk factors were involved in the HCC prognosis, including tumor size, tumor quantity, degree of inflammation, and hepatitis virus (HBV), etc.[4](#cam42169-bib-0004){ref-type="ref"}, [5](#cam42169-bib-0005){ref-type="ref"}, [6](#cam42169-bib-0006){ref-type="ref"} Among them, HBV attributed to be the major reason for HCC in China.[7](#cam42169-bib-0007){ref-type="ref"} Nowadays, the research on HCC is inseparable from the discussion of HBV.

So far, some studies had focused on the associations between HBV genotypes, key mutations, and HCC prognosis. The determination of the HBV genotype is defined based on whether the difference between the groups of the complete genomic sequence exceeds 8%.[8](#cam42169-bib-0008){ref-type="ref"}, [9](#cam42169-bib-0009){ref-type="ref"}, [10](#cam42169-bib-0010){ref-type="ref"} The effects for HCC risk have been certified endemic in China.[11](#cam42169-bib-0011){ref-type="ref"} Moreover, the HBV genotypes have also been proved to implicate with other liver diseases and influence on interferon treatment.[12](#cam42169-bib-0012){ref-type="ref"}, [13](#cam42169-bib-0013){ref-type="ref"}, [14](#cam42169-bib-0014){ref-type="ref"} On the other hand, HBV precore mutations for the HBV‐related HCC (HBV‐HCC) cancer risk have been well studied in recent years.[15](#cam42169-bib-0015){ref-type="ref"}, [16](#cam42169-bib-0016){ref-type="ref"}, [17](#cam42169-bib-0017){ref-type="ref"} The A1762T/G1764A mutations of basal core promoter (BCP) and PreC/C nt1915, nt1896 mutational sites independently impact the postoperative survival of HCC patients.[18](#cam42169-bib-0018){ref-type="ref"}, [19](#cam42169-bib-0019){ref-type="ref"}, [20](#cam42169-bib-0020){ref-type="ref"} However, whether HBV genotypes taking together with mutations impact the HCC prognosis is still confusing.[21](#cam42169-bib-0021){ref-type="ref"} As a continuity of our previous study,[15](#cam42169-bib-0015){ref-type="ref"} which has identified HBV genotype C and EnhII/BCP/PC mutations were associated with HCC risk, we recruited 331 HCC patients as a case‐cohort to evaluate the prognostic effects of HBV genotypes and EnhII/BCP/PC mutations in a Chinese Population.

2. PATIENTS AND METHODS {#cam42169-sec-0006}
=======================

2.1. Patients {#cam42169-sec-0007}
-------------

The patients were reported in our previous study.[22](#cam42169-bib-0022){ref-type="ref"} Briefly, we recruited 414 HCC patients from the First Affiliated Hospital of Nanjing Medical University and Nantong Tumor Hospital and in China. Date of patients' enrollment was defined as baseline‐time. The date of death or the last follow‐up was defined as outcome time. During the follow‐up, we prospectively telephone followed up all patients every 3 months. Patients who smoked one cigarette per day for over one year were defined as smokers, and those who consumed one or more alcohol drinks a week for over 6 months were categorized as alcohol drinkers. Taking account of population heterogeneity: (1) patients who had undergone tumor surgery were excluded in our study; (2) patients with Barcelona Clinic Liver Cancer (BCLC) classification B and C grade were included.[23](#cam42169-bib-0023){ref-type="ref"} Finally, 331 HCC patients who had completed follow‐ups and baseline information were included in this study. The final response rate was 80.0%. Age ranged from 21 to 89, with 284 males and 47 Females. The median survival time was 14.5 months.

2.2. Serological HBV and HCV detecting {#cam42169-sec-0008}
--------------------------------------

We use the platform of enzyme linked immunosorbent assay to detect serum HBsAg and anti‐HCV of all the patients (Kehua, Shanghai, China).

2.3. Detection of HBV genotypes and subgenotypes {#cam42169-sec-0009}
------------------------------------------------

Using the High Pure Viral Nucleic Acid kits (Roche, Mannheim, Germany), we extracted virus nucleic acid from 200 L serum of the included patients. Nested‐PCR was then used to amplify target genome.[15](#cam42169-bib-0015){ref-type="ref"} In the first round PCR, common primer P1‐S (TTTGCGGGTCACCATATTCTTGG) and P1‐AS (CGAACCACTGAACAAATGGCACTAG) was used to enrich region including genotype A, B, C, D. Genotype‐specific primers were then used to amplify genotype A, B, C, D, the detailed primer sequence were listed in our previous study.[15](#cam42169-bib-0015){ref-type="ref"} All of the experiments were blindly performed. PCR assays of different samples were added into single PCR tubes. The success rates of genotypes were over 90%.

2.4. HBV mutation detection {#cam42169-sec-0010}
---------------------------

EnhII/BCP/PC region was amplified by nested‐PCR. The primers of the nested‐PCR were listed in our previous study.[15](#cam42169-bib-0015){ref-type="ref"} The amplified products were then purified and sequenced by using ABI PRISM BigDye sequencing kits and an ABI 3730 Genetic Analyser (Applied Biosystems, CA). The sequences were aligned and analyzed using MEGA 6.0 software. Wild type at each site was defined as the nucleotide with the highest frequency among the HBV persistent carriers. Nucleotide substitutions with the other three nucleotides or indels were defined as mutations. A site with combined SNV frequencies \>10% was defined as a hotspot.

2.5. Statistical analysis {#cam42169-sec-0011}
-------------------------

Median survival time (MST) was summarized to describe the time‐to‐event data, otherwise mean survival time was presented. Kaplan‐Meier method was used to estimate survival. The association between MST and demographic characteristics, clinical features and different genotypes was estimated by log‐rank test. In the analysis of risk factors, univariate and multivariable Cox proportional hazard regression models were performed to estimate the hazard ratio (HR) for HCC, adjusted for age at baseline, gender (male and female), smoking status (no or yes), drinking status (no or yes), BCLC stage (stage B and C), and chemotherapy or TACE (transcatheter hepatic arterial chemoembolization) status (none or yes). To determine the predictors of HCC prognosis, we further performed Stepwise Cox regression model, and set a logically significant level with *P* \< 0.050 for entering and *P* \> 0.050 for removing. The heterogeneity between subgroups was analyzed with the Chi‐square‐based Q test. We used Statistical Analysis System software (version 9.1.3; SAS Institute, Cary, NC). All tests were two‐sided and the statistical significance level was set at *P* \< 0.05.

3. RESULTS {#cam42169-sec-0012}
==========

The characteristics and clinical features of all patients were described previously.[22](#cam42169-bib-0022){ref-type="ref"} In brief, patients' survival time was significantly influenced by drinking and chemotherapy or TACE status. As seen in Table [1](#cam42169-tbl-0001){ref-type="table"}, the frequency of genotype C was higher in never‐drinker and stage C patients than genotype B (*P* = 0.017, 0.011 in different drinking status and BCLC stage, respectively).

###### 

Characteristics of patients at listing according to HBV genotypes

  Variables              HBV genotypes   *P* value                
  ---------------------- --------------- ----------- ------------ -------
  Age                                                             
  ≤53                    23 (14.6)       13 (8.3)    121 (77.1)   0.991
  \>53                   21 (14.2)       12 (8.1)    115 (77.7)   
  Gender                                                          
  Male                   39 (14.9)       24 (9.2)    198 (75.9)   0.147
  Female                 5 (11.4)        1 (2.3)     38 (86.4)    
  Smoking status                                                  
  No                     11 (9.8)        7 (6.3)     94 (83.9)    0.101
  Yes                    33 (17.1)       18 (9.3)    142 (73.6)   
  Drinking status                                                 
  No                     11 (9.2)        6 (5.0)     102 (85.7)   0.017
  Yes                    33 (17.7)       19 (10.2)   134 (72.0)   
  BCLC stage                                                      
  Stage B                44 (15.8)       23 (8.3)    211 (75.9)   0.011
  Stage C                0 (0)           2 (7.4)     25 (92.6)    
  Chemotherapy or TACE                                            
  None                   11 (12.6)       11 (12.6)   65 (74.7)    0.213
  Yes                    33 (15.1)       14 (6.4)    171 (78.4)   
  All patients           44 (14.4)       25 (8.2)    236 (77.4)    

Abbreviations: BCLC, Barcelona Clinic Liver Cancer stage; CI, confidence intervals; HR, hazard ratio; TACE, transcatheter hepatic arterial chemoembolization.

John Wiley & Sons, Ltd

There was no significant association between HBV genotypes and HCC survival (Table [2](#cam42169-tbl-0002){ref-type="table"}). Multivariate Cox regression model was further applied to select HBV mutations which associated with HCC survival, with adjustment----for age, sex, drinking and smoking status, chemotherapy or TACE, and BCLC stage. Mutation nt1753 was associated with HCC prognosis (Log‐rank *P* = 0.034; HR = 0.73, 95% CI = 0.55‐0.97, *P* = 0.035) (Table [3](#cam42169-tbl-0003){ref-type="table"}). Kaplan‐Meier plot of HCC patients' overall survival by nt1753 mutation was shown in Figure [1](#cam42169-fig-0001){ref-type="fig"}. When we used multivariate stepwise Cox regression analysis, nt1753 sustained in the last predictive model together with age, drinking status, and therapy status (HR = 0.72, 95% CI = 0.56‐0.93, *P* = 0.013) (Table [4](#cam42169-tbl-0004){ref-type="table"}).

###### 

HBV genotype frequencies and HCC survival

  HBV genotype   HCC Patients   Deaths        MST     Log‐rank   Crude HR           *P* value   Adjusted HR        *P* value[a](#cam42169-note-0005){ref-type="fn"}
  -------------- -------------- ------------- ------- ---------- ------------------ ----------- ------------------ --------------------------------------------------
  Model 1                                                                                                          
  B              44 (14.43)     34 (11.15)    13.54              1                  ---         1                  ---
  BC             25 (8.20)      20 (6.56)     14.29   0.644      1.11 (0.64‐1.93)   0.705       0.74 (0.42‐1.31)   0.298
  C              236 (77.38)    184 (60.33)   14.69   0.617      0.91 (0.63‐1.32)   0.620       0.86 (0.59‐1.25)   0.423
  Model 2                                                                                                          
  B related      69 (22.62)     54 (17.70)    14.29              1                  ---         1                  ---
  Non‐B          236 (77.38)    184 (60.33)   14.69   0.398      0.88 (0.65‐1.19)   0.399       0.97 (0.71‐1.33)   0.837

B related genotypes including B, BC. Non‐B genotypes including C, D. Abbreviation: HCC, hepatocellular carcinoma.

Cox proportional hazard regression analyses adjusted for age, gender, smoke, drink, BCLC stage, and chemotherapy or TACE.

John Wiley & Sons, Ltd

###### 

The frequencies of the nucleotide substitutions in the EnhII/BCP/PC region of HBV in the HCC patients and HCC survival

  Substitutions   HCC Patients   Deaths        MST     Log‐rank   Crude HR           *P*value   Adjusted HR[a](#cam42169-note-0006){ref-type="fn"}   *P* value[a](#cam42169-note-0006){ref-type="fn"}
  --------------- -------------- ------------- ------- ---------- ------------------ ---------- ---------------------------------------------------- --------------------------------------------------
  C1653T                                                                                                                                             
  C               201 (74.2)     160 (79.6)    14.69   ---        1                  ---        1                                                    ---
  T               70 (25.8)      52 (74.3)     10.71   0.868      1.03 (0.75‐1.41)   0.868      0.93 (0.67‐1.27)                                     0.635
  C1673T                                                                                                                                             
  C               229 (84.5)     178 (77.7)    13.54   ---        1                  ---        1                                                    ---
  T               42 (15.5)      34 (81.0)     13.54   0.495      1.14 (0.79‐1.64)   0.496      1.22 (0.84‐1.78)                                     0.293
  T1674C/G                                                                                                                                           
  T               193 (71.2)     151 (55.7)    13.34   ---        1                  ---        1                                                    ---
  C/G             78 (28.8)      61 (22.5)     16.00   0.659      0.94 (0.69‐1.26)   0.660      0.84 (0.62‐1.14)                                     0.255
  A1703G                                                                                                                                             
  A               231 (85.2)     178 (65.7)    13.54   ---        1                  ---        1                                                    ---
  G               40 (14.8)      34 (12.6)     14.29   0.753      1.06 (0.73‐1.53)   0.753      1.05 (0.72‐1.52)                                     0.814
  G1719T                                                                                                                                             
  G               88 (32.5)      70 (25.8)     14.49   ---        1                  ---        1                                                    ---
  T               183 (67.5)     142 (52.4)    12.85   0.603      0.93 (0.70‐1.24)   0.604      0.87 (0.65‐1.17)                                     0.353
  A1726C                                                                                                                                             
  A               233 (86.0)     184 (67.9)    13.54   ---        1                  ---        1                                                    ---
  C               38 (14.0)      28 (10.3)     13.54   0.860      1.04 (0.70‐1.54)   0.860      0.99 (0.66‐1.48)                                     0.954
  T1727A/G                                                                                                                                           
  T               42 (15.5)      32 (76.2)     13.54   ---        1                  ---        1                                                    ---
  A/G             229 (84.5)     180 (78.6)    13.54   0.556      0.89 (0.61‐1.30)   0.557      0.94 (0.64‐1.38)                                     0.752
  C1730G                                                                                                                                             
  C               229 (84.5)     181 (79.0)    13.44   ---        1                  ---        1                                                    ---
  G               42 (15.5)      31 (73.8)     14.49   0.778      1.06 (0.72‐1.55)   0.778      1.02 (0.69‐1.51)                                     0.904
  A1752G                                                                                                                                             
  A               242 (89.3)     191 (78.9)    13.44   ---        1                  ---        1                                                    ---
  G               29 (10.7)      21 (72.4)     15.47   0.872      0.96 (0.61‐1.51)   0.872      1.06 (0.67‐1.67)                                     0.809
  T1753C                                                                                                                                             
  T               176 (64.9)     142 (80.7)    12.58   ---        1                  ---        1                                                    ---
  C               95 (35.1)      70 (73.7)     16.30   0.034      0.73 (0.55‐0.97)   0.035      0.75 (0.56‐1.01)                                     0.059
  A1762T                                                                                                                                             
  A               51 (18.8)      39 (76.5)     14.49   ---        1                  ---        1                                                    ---
  T               220 (81.2)     173 (78.6)    13.54   0.765      1.05 (0.74‐1.49)   0.766      1.05 (0.74‐1.49)                                     0.789
  G1764A                                                                                                                                             
  G               33 (12.2)      23 (69.7)     14.46   ---        1                  ---        1                                                    ---
  A               238 (87.8)     189 (79.4)    13.54   0.700      1.09 (0.71‐1.68)   0.701      1.07 (0.69‐1.66)                                     0.757
  A1762T/G1764A                                                                                                                                      
  A/G             32 (9.7)       22 (73.9)     14.46   ---        1                  ---        1                                                    ---
  T/A             299 (72.2)     236 (79.5)    14.29   0.699      1.09 (0.70‐1.69)   0.699      1.08 (0.70‐1.68)                                     0.723
  G1799C                                                                                                                                             
  G               48 (17.7)      36 (75.0)     14.69   ---        1                  ---        1                                                    ---
  C               223 (82.3)     176 (78.9)    12.85   0.983      1.00 (0.70‐1.44)   0.983      1.15 (0.80‐1.66)                                     0.457
  A1846T                                                                                                                                             
  A               172 (63.5)     139 (80.8)    13.34   ---        1                  ---        1                                                    ---
  T               99 (36.5)      73 (73.7)     14.46   0.585      0.92 (0.70‐1.23)   0.585      0.95 (0.71‐1.27)                                     0.728
  G1896A                                                                                                                                             
  G               119 (43.9)     94 (79.0)     15.47   ---        1                  ---        1                                                    ---
  A               152 (56.1)     118 (77.6)    13.01   0.245      1.17 (0.89‐1.54)   0.246      1.23 (0.94‐1.63)                                     0.137
  G1899A                                                                                                                                             
  G               187 (69.00)    152 (81.28)   12.85   ---        1                  ---        1                                                    ---
  A               84 (31.00)     60 (71.43)    16.10   0.067      0.76 (0.56‐1.02)   0.068      0.69 (0.51‐0.95)                                     0.020
  G1915A/C                                                                                                                                           
  G               229 (84.5)     177 (77.3)    14.65   ---        1                             1                                                     
  A/C             42 (15.5)      35 (83.3)     11.56   0.653      1.09 (0.76‐1.56)   0.654      1.44 (0.98‐2.10)                                     0.061
  C1969T                                                                                                                                             
  C               234 (86.4)     181 (77.4)    13.70   ---        1                             1                                                     
  T               37 (13.7)      31 (83.8)     12.42   0.766      1.06 (0.72‐1.55)   0.766      1.11 (0.76‐1.64)                                     0.581
  A1979G                                                                                                                                             
  A               230 (84.9)     181 (78.7)    13.54   ---        1                             1                                                     
  G               41 (15.1)      31 (75.6)     14.95   0.396      0.85 (0.58‐1.24)   0.397      0.83 (0.56‐1.22)                                     0.341

Cox proportional hazard regression analyses adjusted for age, gender, smoke, drink, BCLC stage, and chemotherapy or TACE.

John Wiley & Sons, Ltd

![Kaplan‐Meier plots of HCC patients' overall survival by nt1753 mutation, log‐rank *P* = 0.034. X‐axis, HCC patients' survival time (months); Y‐axis, HCC patients' survival probability](CAM4-8-3086-g001){#cam42169-fig-0001}

###### 

Multivariate Cox regression analysis on HCC patients' survival

  Variables                          β[a](#cam42169-note-0008){ref-type="fn"}   SE[b](#cam42169-note-0009){ref-type="fn"}   HR (95% CI)        *P* value
  ---------------------------------- ------------------------------------------ ------------------------------------------- ------------------ -----------
  Stepwise regression analysis                                                                                                                 
  Chemotherapy or TACE (yes vs no)   −0.7585                                    0.1513                                      0.47 (0.35‐0.63)   \<0.001
  Age (\>53 vs ≤53)                  −0.4753                                    0.1352                                      0.62 (0.48‐0.81)   \<0.001
  nt1753 (C vs T)                    −0.3224                                    0.1299                                      0.72 (0.56‐0.93)   0.013
  Drinking status (yes vs no)        0.3451                                     0.1283                                      1.41 (1.10‐1.82)   0.007

*P*: Cox proportional hazard regression analyses adjusted for age, gender, smoke, drink, BCLC stage, chemotherapy or TACE and HBV genotype and mutations.

β is the estimated parameter of the regression model.

SE is the standard error of the regression model.

John Wiley & Sons, Ltd

Stratification analysis was performed to evaluate the different effects of nt1753 on HCC survival, according to subgroups of demographic characteristics, BCLC stage, and therapy status (Table [5](#cam42169-tbl-0005){ref-type="table"}). We found the results that the effect of nt1753 was more significant in non‐B genotype (adjusted HR = 0.74, 95% CI = 0.54‐1.02 in Non‐B genotype; adjusted HR = 1.64, 95% CI = 0.69‐3.87 in B genotype; *P* = 0.090 for heterogeneity test). Multiplicative interaction analysis was then performed and slightly significant signal on HCC survival was found between nt1753 genotypes and HBV genotypes (*P* = 0.069) (Table [6](#cam42169-tbl-0006){ref-type="table"}). Crossover analyses revealed that taking subjects with nt1753T genotype and non‐B HBV genotype as reference, patients with nt1753C and non‐B HBV genotype had a significantly decreased hazard of death (HR = 0.73, 95% CI = 0.53‐1.01).

###### 

Stratified analyses of combined effect of nt1753 associated with HCC patients' survival

  Variables              nt1753 (deaths/censor)   Adjusted HR (95% CI)[a](#cam42169-note-0011){ref-type="fn"}   *P* for heterogeneity   
  ---------------------- ------------------------ ------------------------------------------------------------- ----------------------- -------
  Age                                                                                                                                   
  ≤53                    78/15                    37/15                                                         0.77 (0.50‐1.19)        0.654
  \>53                   64/19                    33/12                                                         0.89 (0.56‐1.41)        
  Gender                                                                                                                                
  Male                   20/3                     9/4                                                           0.94 (0.36‐2.47)        0.967
  Female                 122/31                   61/21                                                         0.92 (0.66‐1.29)        
  Smoking status                                                                                                                        
  No                     43/15                    25/10                                                         0.92 (0.53‐1.59)        0.843
  Yes                    99/19                    45/15                                                         0.86 (0.59‐1.26)        
  Drinking status                                                                                                                       
  No                     45/17                    26/11                                                         1.02 (0.60‐1.74)        0.520
  Yes                    97/17                    44/14                                                         0.82 (0.55‐1.22)        
  BCLC stage                                                                                                                            
  Stage B                129/31                   62/23                                                         0.76 (0.55‐1.05)        0.352
  Stage C                13/3                     8/2                                                           1.33 (0.43‐4.14)        
  Chemotherapy or TACE                                                                                                                  
  No                     49/9                     19/5                                                          0.91 (0.50‐1.64)        0.769
  Yes                    93/25                    51/20                                                         0.82 (0.57‐1.18)        
  HBV genotype                                                                                                                          
  B related              38/12                    7/0                                                           1.64 (0.69‐3.87)        0.090
  Non‐B                  98/22                    64/23                                                         0.74 (0.54‐1.02)        

Abbreviations: CI, confidence intervals; HR, hazard ratio.

Adjusted for age, gender, smoke, drink, BCLC stage, Chemotherapy or TACE and HBV genotype.

John Wiley & Sons, Ltd

###### 

Interactive effect of nt1753 and HBV genotype associated with HCC patients' survival

  HBV genotype                         nt1753   Patients      Deaths        Adjusted HR[a](#cam42169-note-0013){ref-type="fn"} (95%CI)   *P* value[a](#cam42169-note-0013){ref-type="fn"}
  ------------------------------------ -------- ------------- ------------- ------------------------------------------------------------ --------------------------------------------------
  Non‐B                                T        123 (46.59)   101 (82.11)   1.00                                                         ---
  Non‐B                                C        84 (31.82)    61 (72.62)    0.73 (0.53‐1.01)                                             0.060
  B related                            T        50 (18.94)    38 (76.00)    0.85 (0.58‐1.25)                                             0.405
  B related                            C        7 (2.65)      7 (100.00)    1.40 (0.64‐3.06)                                             0.402
  *P* for multiplicative interaction   0.069                                                                                             

Abbreviations: CI, confidence intervals; HCC, hepatocellular carcinoma; HR, hazard ratio.

Adjusted for age, gender, smoke, drink, BCLC stage, Chemotherapy or TACE and HBV genotype.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42169-sec-0013}
=============

In this study, we evaluated the effects of HBV genotypes and mutations in EnhII/BCP/PC region on advanced HCC patients' survival and demonstrated that nt1753 may be a potential biomarker to predict the prognosis for patients with advanced HCC.

Our previous large‐scale multi‐center case‐control study [15](#cam42169-bib-0015){ref-type="ref"} indicated that patients with genotype C were more susceptible to develop HCC. This study may provide slight evidence to support the conclusion (shown in Table [1](#cam42169-tbl-0001){ref-type="table"}). In addition, we found that HCC patients with genotype C were prone to suffering more malignant tumors than those with genotype B.

When compared with patients with genotype B, patients with genotype C were in connection with higher HBV load,[24](#cam42169-bib-0024){ref-type="ref"} more serious liver diseases, such as liver cirrhosis or HCC,[25](#cam42169-bib-0025){ref-type="ref"}, [26](#cam42169-bib-0026){ref-type="ref"}, [27](#cam42169-bib-0027){ref-type="ref"} had been reported in several Asian countries. The earlier spontaneous HBeAg seroconversion developed in patients with genotype B, the less progressive liver disease would occur.[28](#cam42169-bib-0028){ref-type="ref"} While evidence for genotype C correlated with poor liver disease outcomes was sounded, genotype C not a predictor for HCC patients' overall survival (OS) in our study. Despite some studies indicated independent risk effects of genotype C for HCC tumor recurrence, we need to be careful drawing conclusions considering the small sample size.[29](#cam42169-bib-0029){ref-type="ref"}, [30](#cam42169-bib-0030){ref-type="ref"}

Nt1753 located in the EnhII region (embedded in X gene) was independently associated with HCC OS, which was the most essential finding in this study. The prospective effect was more pronounced in non‐B genotype. Nt1753 mutation in the region led to the amino acid (aa) transitions at aa127 (I‐to‐T/N/S), and it has been shown to be independently and significantly associated with HCC risk in our previous multi‐center case‐control study.[15](#cam42169-bib-0015){ref-type="ref"} The opposite effect indicated that subjects with nt1753C had a greater risk for developing HCC; afterwards, the survival time of HCC patients with nt1753C were longer than that in patients with nt1753T. In a previous cohort in Taiwan, they found that the HBV e‐antigen (HBeAg)‐negative patients had a higher frequency of mutations of T1753C than HBeAg‐positive patients.[31](#cam42169-bib-0031){ref-type="ref"} Another study showed that clones with mutations at positions 1753/1762/1764 exhibited increased‐replication phenotypes.[32](#cam42169-bib-0032){ref-type="ref"} However, one cross‐sectional analysis in Chinese population found that mutation at 1753/1762/1764 and genotype was not associated with viral loads in either HBeAg or anti‐HBe positive subjects.[33](#cam42169-bib-0033){ref-type="ref"}The association between HBV viral load and mutation of nt1753 was still unclear. Moreover, many studies have demonstrated that a high viral load was an adverse prognostic factor for survival of HBV‐related HCC patients.[34](#cam42169-bib-0034){ref-type="ref"}, [35](#cam42169-bib-0035){ref-type="ref"}, [36](#cam42169-bib-0036){ref-type="ref"} Then the association of T1753C mutation and HBV‐related HCC patients' survival were still controversial. In addition, HBV exist as quasispecies, in which the mutant possesses differing levels of fitness in a range of environments,[37](#cam42169-bib-0037){ref-type="ref"} from chronic hepatitis to advanced HCC. In order to verify the association between nt1753 mutation and HCC survival, large sample population studies or functional experiments are needed in the future.

Surprisingly, the effect of HBV genotypes and mutations on HCC prognosis has not been examined by systematically dissecting EnhII/BCP/PC region. What\'s more, when compared to previous studies, the successful rates of detecting HBV genotypes, subgenotypes, and mutations were more reasonable. However, our study has several limitations as well: moderate sample size needs to increase to ensure the stability of the results; in addition, the HCC patients were followed up by telephone in this study, the cirrhosis diagnosis and the antiviral treatment scheme was not obtained. Therefore, we did not show HBV DNA, ALT and AST level, cirrhosis status in this study; otherwise, external validation with independent population may further solid the findings.

5. CONCLUSIONS {#cam42169-sec-0014}
==============

In conclusion, our study has demonstrated nt1753C in EnhII/BCP/PC region might be an independent predictors for HCC prognosis. Further large population study and functional experiments were needed to polish the conclusion.
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